COMBINATION OF CAR T-CELL THERAPY WITH BTK INHIBITORS AND METHODS OF USE THEREOF

Abstract

The present disclosure provides the use of immune effector cells (e.g., T-cells or NK cells) engineered to express a Chimeric Antigen Receptor (CAR), in combination with a kinase inhibitor (e.g., a BTK inhibitor), for the treatment of a disease or disorder (e.g., a hematological malignancies).

CPC Classifications